

PRESS RELEASE

22 August 2025 17:30:00 CEST

Invitation to Saniona Q2 investor call on 28 August 2025

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, will host a Q2 investor call on 28 August 2025, at 13.00 CEST

At the call Management will be presenting results and a company update. At the end of the presentation there will be a Q&A session, where participants can ask online questions.

Access to the event can be obtained through the following link: Live Q: Saniona - Redeye

REPLAY access

Webcast replay will be available at www.saniona.com and at www.redeye.se

For more information, please contact

Johnny Stilou, CFO, +45 21227227; johnny.stilou@saniona.com

About Saniona

Attachments

Saniona is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders. The company's internal pipeline includes SAN2219 for epilepsy and SAN2465 for major depressive disorder. Saniona has established strategic collaborations with leading pharmaceutical companies, including Jazz Pharmaceuticals, which holds global rights to SAN2355 for epilepsy, Acadia Pharmaceuticals, which holds worldwide rights to ACP-711 for essential tremor, and with Medix, which holds rights to tesofensine for obesity in Mexico and Argentina, where a market authorization application is currently under review. In addition, Saniona has two clinical-stage programs available for partnering: TesometTM, ready to advance to Phase 2b trials in rare eating disorders, and SAN903, ready to enter Phase 1 trials in inflammatory bowel disease. Saniona's ion channel discovery platform is further validated through research collaborations with Boehringer Ingelheim, AstronauTx, and Cephagenix. Headquartered in Copenhagen, Saniona is listed on the Nasdaq Stockholm Main Market.

Email: saniona@saniona.com

Web: saniona.com

Invitation to Saniona Q2 investor call on 28 August 2025